StockData
Altimmune, Inc. logo

Altimmune, Inc. (ALT) income statement

ALTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 4/30
$1.33−0.08 (-5.67%)

Close on Nov 20, 2026Market cap $258.71MP/E –Yield –

See a number that looks wrong?